Regenxbio: A Novel Gene Therapy Innovator With Substantial Unlocked ValueSeeking AlphaNotably, voretigene neparvovec-rzyl (Luxturna) – a one-time gene therapy for patients afflicted with biallelic RPE65 mutation-associated retinal dystrophy – of Sparks… Continue reading
Science DailyA compass in the darkScience DailyStill, the underlying mechanisms remain unknown. "To solve this question might not only satisfy neuroscientific curiosity but also lead to new molecular methods," said Prof. Dr. Gil Gregor Westme… Continue reading
OncLiveImmunotherapy Making Headway in SCLC and MesotheliomaOncLiveImmune-based therapies continue to show promising signals for patients with small cell lung cancer (SCLC) and mesothelioma, but better predictive biomarkers are needed to determine who … Continue reading
OncLiveStudies Highlight Rationale for Immunotherapy in Early-Stage and Locally Advanced NSCLCOncLiveWith durvalumab (Imfinzi) being hailed as a potentially practice-changing therapy in locally advanced non–small cell lung cancer (NSCLC), ongoing studi… Continue reading
CAR-T Cell Therapy: What We Never Dreamed OfCuretoday.comThen there are the side effects associated with CAR-T cells. The most serious is cytokine release syndrome — a “cytokine storm” — that can be life-threatening. Signs of this include fever, nausea… Continue reading
Healio |
VIDEO: CAR T-cell therapy has ‘incredible potency’ in chronic lymphocytic leukemia
Healio NEW YORK — In this video commentary from HemOnc Today New York, co-program chair David L. Porter, MD, discussed the use of chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia. CAR T cells have “incredibly … |
|
CAR T-cell therapy ‘holds great promise’ advanced chronic lymphocytic leukemia
Healio NEW YORK — Chimeric antigen receptor T–cell therapy “holds great promise” for patients with advanced relapsed or refractory chronic lymphocytic leukemia, according to one of the program chairs of HemOnc Today New York. “There are new molecules and new … |
|
Is General Electric’s Future in Biology?
Madison.com To date, synthetic biology start-ups have been forced to master a complete technology platform ranging from the genetic engineering and design of organisms capable of churning out useful chemicals to the design and scale-up of massive facilities. Those … |